AbbVie to Allow Use of Intellectual Property for Coronavirus

AbbVie will allow the use of its intellectual property by other companies around the world to step up treatment for coronavirus patients, the drug company said in an emailed statement.

• AbbVie has provided Kaletra (lopinavir/ritonavir) as an experimental option for treatment of the coronavirus
• All requests for hospitalized patients in Israel are being supplied
• “Given this important public health crisis, AbbVie commits that we will take all steps necessary to remove any potential barriers to alternate sources of supply, including dedicating to the public our intellectual property related to lopinavir/ritonavir.”
  
  • The company will communicate its intention to generic manufacturers
• NOTE: March 19, Israel Uses Powers to Override Drug Patent for Coronavirus Use

To contact the reporter on this story:
Alisa Odenheimer in Jerusalem at aodenheimer@bloomberg.net

To contact the editors responsible for this story:
Shaji Mathew at shajimathew@bloomberg.net

Mark Williams, Yaacov Benmeleh

© 2020 Bloomberg L.P. All rights reserved. Used with permission.